WO2005082561A1 - コロイダル金属 - Google Patents
コロイダル金属 Download PDFInfo
- Publication number
- WO2005082561A1 WO2005082561A1 PCT/JP2005/001796 JP2005001796W WO2005082561A1 WO 2005082561 A1 WO2005082561 A1 WO 2005082561A1 JP 2005001796 W JP2005001796 W JP 2005001796W WO 2005082561 A1 WO2005082561 A1 WO 2005082561A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metal
- colloidal
- gold
- cyclodextrin
- silver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/10—Metallic powder containing lubricating or binding agents; Metallic powder containing organic material
- B22F1/102—Metallic powder coated with organic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
Definitions
- the present invention relates to health foods, cosmetics, pharmaceuticals, and quasi-drugs containing colloidal metals.
- Non-Patent Document 1 introduces a typical sol-gel production mechanism of silver bromide colloid by Sugimoto et al.
- the silver bromide particles are converted to silver oxide particles by photo-oxidation and reduced to silver particles.
- Patent Document 1 by YOUNG, Mark, J et al. Describes a method for producing a protein sensor containing nano-sized metal particles of several nanometers (hereinafter abbreviated as "nm") using a protein cage.
- nm nano-sized metal particles of several nanometers
- proteins are used as cages, it is necessary to strictly confirm safety when using, for example, drugs.
- severe allergic asthma symptoms may result from proteins derived from natural rubber.
- proteins For food and pharmaceutical applications, it is essential to confirm a wide range of safety for proteins, which increases the cost of safety confirmation.
- proteins have a large molecular weight, which is economically disadvantageous as an active ingredient having a low metal content.
- transdermal administration is not possible because it is wrapped in macromolecules. .
- Patent Document 2 by Oh Seong-Geun et al. Describes a method for producing nanosilver particles of 200 nm or less, preferably 20 nm or less, using a metal salt, a reducing agent, polyoxyethylene, sorbitol laurate, and sodium dodecyl sulfate. ing.
- this document describes a method for controlling and manufacturing metal particles of 2 nm or less.
- a hydrazine system is mentioned as a reducing agent. Since metal salts are reduced, there are few problems in health and safety. Hydrazine and its decomposed products are not preferable in health and safety.
- Non-Patent Document 3 by Yali Liu et al. Describes a method for producing gold nanoparticles using cyclodextrin. The law is described. However, nanoparticles have a minimum particle size of only 2 to 4 nm, which is too large to interact with enzymes. This document also describes a method of controlling and manufacturing metal particles of 2 nm or less.
- Non-Patent Document 1 J. Soc.Photogr.Sci Technol. Japan 40, 15-21 (1977)
- Non-Patent Document 2 Lee S Simon, Chung rthritis Advisory Committee March 5, 2003
- Non-Patent Document 3 Chem.Matter, 15,4172-4180 (2003)
- Patent Document 1 WO 2004/001019, PCT / US2003 / 003364
- Patent Document 2 United States Patent 6,660,058
- An object of the present invention is to provide a health food containing colloidal metal or colloidal metal alloy as a medicine which is not a problem on health and safety, and a cosmetic product having a size sufficient to act with enzymes and having an effect of suppressing excessive autoimmunity. It is to provide medicines at a low price.
- the colloidal metal of the present invention includes a metal having a diameter of 0.5 nm or more and 2 nm or less, or a low molecular weight conjugate which is included in an alloy particle thereof.
- the low molecular weight conjugate incorporated with the metal or its alloy particles is cyclodextrin or crown ether, and preferably the cyclodextrin is j8 or and ⁇ or and ⁇ cyclodextrin.
- the number of ring-constituting atoms of the crown ether is preferably from 30 to 99.
- the colloidal metal of the present invention particularly colloidal gold and gold alloy, have an inhibitory effect on melanin production and an inhibitory effect on melanocyte proliferation, and are used for rheumatic agents, antiallergic agents, anti-black skin. It is also effective as a skin cancer agent. Since the particle size is as small as 0.5 nm or more and 2 nm or less in molecular size, it can be absorbed percutaneously, and a small amount can be administered to affected parts in a small amount as needed. Side effects can be prevented beforehand. In addition, it has less side effects because it is a metal that is less than trivalent and highly toxic gold ions such as gold thiomaleic acid. It is also more stable than ion when used as a health food.
- the colloidal metal of the present invention includes a metal having a diameter of not less than 0.5 nanometer and not more than 2 nanometer or a low molecular weight conjugate which is included in an alloy particle thereof.
- the low molecular weight conjugate incorporated with the metal or its alloy particles is cyclodextrin or crown ether, and preferably the cyclodextrin is j8 or and ⁇ or ⁇ cyclodextrin.
- the number of ring-constituting atoms of the crown ether is 30 to 99.
- the present invention contemplates that gold or gold alloy particles having a size of 0.5 to 2 nm have an inhibitory effect on the production of melanocytes and a melanocyte proliferation, and that they have an effect as an inhibitor of excessive autoimmune action. As a result, the pharmaceuticals and cosmetics of the present invention were completed.
- Raw materials for the colloidal metal of the present invention include water-soluble metal salts such as chelate salts, nitrates and hydrochlorides.
- Organic salts such as acetates may be used as long as they have appropriate water solubility.
- the metal salt is provided as an aqueous solution or an aqueous alcohol solution.
- silver nitrate aqueous solution Liquid, aqueous solution of 4 salted gold acid, etc. and may be used as a mixture.
- the concentration of the raw material metal salt aqueous solution or alcohol aqueous solution is preferably 50 ppm or less in terms of metal in order to control the diameter of metal particles different depending on the metal. More preferably, it is below 20 ppm. In the case of an inert metal, such as gold, it is less than 10 ppm, more preferably less than 5 ppm. The higher the metal salt concentration, the wider the particle size distribution, and the more likely secondary aggregation occurs.
- Examples of the reducing agent include natural hydroxycarboxylic acids such as citric acid, malic acid, oxalic acid, ascorbic acid, and lactic acid, and alkali metal salts thereof, dalcoviranose, dalcofuranose, mannose, saccharose, ratatose, xylitol, agarose, and sonorebit. And dextrin and the like, and alcohols such as isopropyl alcohol, ethyl alcohol, glycerin, ethylene glycol, and propylene glycol.
- These reducing agents are relatively mild reducing agents.
- a reducing agent that is as mild as possible.
- gold or gold alloy which is stable as a metal, is preferably a low-molecular alcohol which is the mildest reducing agent, for example, methanol, ethanol, propanol, glycerin and the like.
- a low molecular weight inclusion compound is used as a host that serves as a metal reduction deposition site for gold or gold alloy.
- low molecular weight inclusion compounds include, for example, cyclodextrin and crown ether. Cyclodextrin is a natural product and is excellent in safety and economy.
- Cyclodextrin as an inclusion compound is formed from a of a 6-membered glucose ring.
- the pore diameter of a cyclodextrin is about 0.45 nm
- a 7-membered ring j8 cyclodextrin is 0.7 nm
- an 8-membered ring 0 cyclo Dextrin has a wavelength of 0.85 nm
- 9-membered ⁇ -cyclodextrin has a wavelength of 0.90 nm.
- the atomic diameter is large, so that a cyclodextrin having 7 or more members is more preferable, and a cyclodextrin having more than 8 members is more preferable.
- Cyclodextrin is in a bucket-like form, In some cases, the metal particles are included by being sandwiched from below. In this case, it acts as a hole about twice as large as the hole diameter. Cyclodextrin serves as a metal reduction deposition site for the gold or gold alloy of the present invention.
- the minimum number of gold atoms constituting one gold particle used in the present invention is about ten, and when a body-centered cubic lattice is formed, its size becomes about 0.5 nm.
- the required minimum number of seats of the inclusion compound is the number of moles divided by this number of constituent atoms. Therefore, the concentration is preferably at least 1/10 mol of the molar concentration of metal. It is economically disadvantageous to use an excess of the inclusion compound.
- the molar concentration of the metal is preferably equimolar or more. More preferably, it is twice or more equimolar.
- crown ethers as inclusion compounds include ordinary polyethylene oxide crown ethers in which a hetero atom is oxygen, polyoxythioxide type thio crown ethers in which a hetero atom is sulfur, and nitrogen in a hetero atom. And sulfur, such as azacho crown ether.
- the inside diameter of the crown ether used in the present invention is 0.5 to 2 nm, and the number of atoms constituting the ring is 30 to 99.
- the inner diameter of 30-crown ether-1 10 is about 0.53 nm, and the inner diameter of 51-crown ether 117 is about 0.96 nm.
- the inner diameter of 99 Crownet 33 is about 2 nm.
- the crown ether is produced by preparing a polyethylene oxide having a halogen such as chlorine at both terminals, for example, heptaethylene oxide dichloride and a polyethylene oxide, for example, heptaethylene oxide, in a tetrahydrofuran (hereinafter abbreviated as “THF”) solution in hydroxylic acid.
- THF tetrahydrofuran
- the concentration is preferably 1/10 or more of the molar concentration of the metal. Excessive use of inclusion compounds is economically disadvantageous. For practical control of particle size, equimolar or higher molar concentrations of metal are preferred. More preferably, it is twice or more equimolar.
- a pre-cooled aqueous solution of a metal salt diluted to a prescribed concentration pre-cooled is added to an aqueous solution of cyclodextrin or an aqueous alcohol solution while stirring, and an aqueous solution of a reducing agent is gradually added.
- the temperature is raised to accelerate the reaction.
- it is important to reduce the reaction amount and reaction rate. If necessary, irradiate light such as ultraviolet light to promote the reaction. Is also good. It is preferable to perform a nitrogen flow in order to prevent air oxidation due to stirring.
- the reaction temperature varies depending on the reaction system, but it is preferable from the viewpoint of size control that the components are cooled to 5 ° C or less for each component, mixed, and then gradually heated to a predetermined reaction temperature. It is preferable to carry out the reaction as slowly as possible in order to control the size and to prevent secondary agglomeration and the like, and to carry out the reaction at a low concentration and at a low temperature which are preferable for a long time.
- the reaction temperature is preferably from 10 ° C. to 50 ° C. In order to improve the particle size yield of 2 nm or less, a mild reaction is preferable, and the reaction time is preferably 10 hours or more.
- the reaction vessel is preferably a glass, glass-lined or polyethylene-lined vessel. It is preferable to sufficiently wash the container in advance with a nitric acid aqueous solution or the like to prevent impurities from being mixed.
- the water is preferably ion-exchanged with distilled water to remove metal components in advance.
- Gold is a poorly reactive metal. Gold is added as gold leaf to foods such as sake, rikamaboko and confectionery, but has been approved as a food additive in Japan and its safety has been confirmed. However, it is considered that metallic gold is hardly absorbed in the body.
- the cleaning of the affected area with the stone according to the present invention also has the effect of removing sebum components such as sweat glands and pores, which are the main routes of percutaneous absorption.
- sweat glands are opened due to an increase in skin temperature during bathing, and absorption efficiency is improved. It is considered that this has improved.
- the physical effect of the washing was to extract the gold particles of the inclusion compound and to easily absorb them into the lymph.
- the size of the colloidal metal or metal alloy of the present invention is about the same as the size of the active site of this enzyme, and is 2 nm or less, more preferably 1.5 nm or less, still more preferably 1. Onm or less. It is 0.5 nm or more that can form a large crystal lattice.
- Sunburn causes darkening of the skin, which is caused by the stimulation of ultraviolet light, which causes the skin to turn red and melanin-producing cells (melanocytes) that have been commanded by the brain power to actively produce melanin.
- the enzyme involved in the production of melanin is tyrosinase. Copper is stored in the liver, but is transported to the skin by brain commands and deposited in cystine, a melanocyte. Tyrosinase is activated by binding to copper, which also transfers cystine power, and contributes to melanin production.
- gold previously transdermally delivered to the cystine instead of the copper the carried copper cannot be deposited in the cystine, and tyrosinase cannot be activated.
- the colloidal gold of the present invention can contribute to skin whitening effect by transdermal administration.
- the colloidal gold of the present invention was transdermally administered immediately after redness due to sunburn, the skin turned black. This indicates that transdermal administration suppressed melanin production. Is shown.
- the present inventors transdermally administered 0.1 lml of the colloidal gold aqueous solution of the present invention at a concentration of 5 ppm to the skin of a 2-cm square back part of a 6-week-old female brown guinea pig shaved hair once daily for 14 days.
- a concentration of 5 ppm to the skin of a 2-cm square back part of a 6-week-old female brown guinea pig shaved hair once daily for 14 days.
- FIG. 1 adjacent blank site
- the method of administering the colloidal metal of the present invention is not limited to the above-mentioned transdermal method.
- Oral administration is also possible as exemplified in the description of health foods.
- the transdermal administration of the colloidal gold particles of the present invention stopped the abnormal growth of melanocytes.
- the abnormal growth of skin cells is benign, such as warts, fish eyes, spots, and moles; if malignant, it results in black skin cancer. Therefore, the transdermal administration of the colloidal gold particles of the present invention is promising as a therapeutic agent for black skin cancer.
- the colloidal gold and gold alloy particles of the present invention are fine at the molecular level, the skin force is rapidly absorbed as is clear from guinea pig experiments. In particular, it is expected that power such as sweat glands and pores will also be absorbed. Accordingly, by adding and blending the colloidal gold of the present invention to cosmetic drapes, lotions, stones, shipping agents, and the like, skin whitening and spot removal effects can be imparted. Further, it can be used as a transdermal drug as a rheumatic chronic arthralgia drug and an anti-skin cancer drug.
- the colloidal gold and gold alloy of the present invention can be directly administered to the site of action, and act on enzymes relating to autoimmunity, etc., so that the amount of the drug to be used may be very small.
- the dose of general drugs is several mg
- the amount of additives added to cosmetic creams, lotions, stones, shipping agents, etc. is effective at 5 ppb or more in terms of gold.
- This dose is in the unit of number; zg, and is very small and effective compared to general drugs. This is very preferable in terms of safety such as side effects of the drug.
- the concentration of the colloidal gold of the present invention is preferably lOppb or more, more preferably lOOppb or more, when different forces S are required at an early stage depending on the required drug effect. More preferably, it is 200 ppb or more.
- the colloidal gold aqueous solution or the alcohol aqueous solution of the present invention is applied to the cream, lotion, stone, shipping agent or the like. It can be easily manufactured by mixing with raw materials such as Upon stirring, the stirring method may be appropriately selected depending on the viscosity, such as using a mixer if the product viscosity is large, and using a homomixer if the product viscosity is small. It is preferable to perform a nitrogen purge at the time of stirring, in terms of preventing oxidization.
- colloidal gold or gold alloy of the present invention reacts with a thiol group or a diacylimide group
- compounds having these functional groups in raw materials and additives such as creams, lotions, stones and shipping agents should be avoided. preferable.
- Other colorants, viscosity improvers, stabilizers, fragrances, preservatives, and other medicinal ingredients that do not cause side effects can be used in general, as long as there is no problem in performance.
- an additive such as a thickener can be added to the colloidal metal of the present invention, if necessary, as long as the properties of the colloidal metal of the present invention are not hindered.
- water-soluble dextrin, starch, gum arabic, gelatin, polydalicol, etc. can be used as thickeners and auxiliary protective colloids. Wear.
- silver As is known for silver tableware, silver has long been used as an antibacterial agent. The effect is said to be due to the silver ion binding to the thiol group of cystine, which inhibits the sulfide bond. It has been observed that silver ions aggregate around intracellular sulfur. The colloidal silver of the present invention also reacts with thiol groups. However, silver ions have a high reactivity and a large binding energy, but the colloidal silver of the present invention is more stable than silver ions so that it can be produced even under weakly acidic conditions such as reduction with citric acid, and there is a risk of discoloration. Few.
- Tap water may also contain silver depending on the geology.
- RID oral intake
- RED Registration Eligibility Document
- aqueous colloids of silver particles or silver ions with a concentration of several tens of nm at a concentration of 50 ppm are sold in the United States as health food under the Dietary Supplement Health and Education Act (DSHEA).
- Cosmetics contain water, are kept at room temperature even after opening, and contain a large amount of nutrients, so that bacterial growth is likely to occur.
- Parabens (benzoic esters) are widely used as preservatives, but they are not sufficient in terms of safety.
- the colloidal silver and silver alloy of the present invention also contain silver as a main component, and have antibacterial properties which effectively act as antibacterial agents and preservatives.
- the turbidity measurement using a liquid medium Soybean-Casein Digest Broth, manufactured by BECTON DICKINSON AND CAMPANY
- Staphylococcus aureus JCM No.2151 was cultured at 32 ° C for 3 days and at 23 ° C for Candida bacteria.
- the minimum growth inhibitory concentration obtained after culturing for 3 days was excellent at 20 ppm. This value was the same as that of the silver nitrate used as the comparative product, and was about 1 Z25 for an antibacterial agent such as a zeolite silver-substituted product.
- the zeolite silver substitute showed insufficient antibacterial properties and exhibited antibacterial performance that could be used as a powerful preservative that could not be used. Therefore, it can be used in a zeolite silver-substituted product to reduce the use of antibacterial agents, for example, the effect of bacterial propagation on the skin, and has antibacterial and deodorant properties as a skin cleanser at low concentrations.
- a gold-containing concentration cooled to 5 ° C lOOppm A solution of 1,400 ppm of cyclodextrin as a protective colloid in 200 ml of an aqueous solution of salted acid and 200 ml of an aqueous solution of 1,400 ppm of cyclodextrin and a monosodidium citrate salt as a reducing agent were equimolarly divided into 4 parts per mole of gold.
- the temperature was raised to 40 ° C at a rate of 2 ° C per minute with stirring while purging with nitrogen, and after reaching 40 ° C, the temperature was maintained for 1 hour to carry out the reduction reaction, and then divided into equimolar portions.
- the remaining reducing agent thus obtained was repeatedly reacted in the same manner to produce almost colorless 33 ppm colloidal gold of the present invention.
- the average particle size of the colloidal gold nanoparticles was determined by placing colloidal gold on the mesh of the collodion film and analyzing the transmission electron micrographs. The particle size distribution of the gold particles was divided into the smallest group of lOnm or more, and the average diameter of the smallest drop was about 0.9 nm, which was almost the same as the pore size of j8 cyclodextrin. Many particles smaller than 2 nm could be observed.
- the produced colloidal gold was stored at room temperature for 30 days, but was stable and did not show any discoloration or secondary aggregation.
- Comparative Example 1 for colloidal gold using a water-soluble dextrin having a molecular weight of about 10,000 instead of ⁇ -cyclodextrin, partial secondary aggregation with a large average particle size of 5.7 nm was observed. Further, for reference, when the reduction reaction was performed at 90 ° C. or higher, the reaction was instantaneous and the color became reddish, the particle size of all the gold nanoparticles was 10 nm or more, and no gold nanoparticles of 2 nm or less were observed.
- colloidal silver contained particles having an average diameter of the smallest group, and a large number of these particles could be observed even after 10 hours.
- ⁇ cyclodextrin became a nucleus for silver metal precipitation.
- the particles were prevented from becoming excessive as protective colloid.
- it was stored at room temperature for 30 days, but it was stable and showed no discoloration or secondary aggregation. All raw materials and products after the reaction were safe enough to be used as food additives
- Example 2 After the solid coconut oil stone ⁇ was finely cut, the same 5 ppm colloidal gold of the present invention of Example 2 was swelled and dissolved in an equal volume of 40 ° C. hot water. The colloidal gold lOOppb of the present invention was used to produce a solid stone II for treating rheumatoid arthritis of the present invention.
- the 5 ppm colloidal gold of the present invention produced in Production Example 2 was diluted with water and ethanol so as to be 1 OOppb and 15% of ethanol, to produce the lotion for whitening of the present invention.
- Silver content lOppm Silver nitrate aqueous solution 150ml was added with gold content 5ppm chloroauric acid solution 50ml, and the reduction reaction was carried out in the same manner as in Example 2 to produce a pale yellow 12.5ppm colloidal silver-gold alloy of the present invention. did.
- the average particle size of the silver-gold alloy particles of the colloidal silver-gold alloy was determined by image analysis of a transmission electron micrograph of the colloidal silver-gold alloy placed on a mesh of a collodion film.
- the minimum group average particle size of the silver-gold alloy nanoparticles was about 0.8 nm, which was almost the same as the pore size of j8 cyclodextrin. X-ray fluorescence confirmed that silver and gold coexisted in the metal particles and that the metal particles were silver-gold alloy.
- colloidal gold having a concentration of 5 ppm of light purple gold of the present invention produced by changing the / 3 dextrin to 30-crown only 10 was produced.
- Colloidal gold nanoparticles The average particle size of was determined from transmission electron micrographs of colloidal gold placed on a mesh of a collodion film. Most of the gold nanoparticles ranged from 0.5 to 2 nm and were about the same size as the 30-crown-10 pore size or twice as large.
- FIG. 1 Comparison of melanin production after 14-day administration of brown guinea pigs.
- FIG. 2 A transmission electron micrograph of the colloidal gold of the present invention
- FIG. 3 is a transmission electron micrograph of the colloidal silver of the present invention.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Manufacture Of Metal Powder And Suspensions Thereof (AREA)
- Powder Metallurgy (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510385A JPWO2005082561A1 (ja) | 2004-02-27 | 2005-02-08 | コロイダル金属 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004052582 | 2004-02-27 | ||
JP2004-052582 | 2004-02-27 | ||
JP2004110595 | 2004-04-05 | ||
JP2004-110595 | 2004-04-05 | ||
JP2004179031 | 2004-06-17 | ||
JP2004-179031 | 2004-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005082561A1 true WO2005082561A1 (ja) | 2005-09-09 |
Family
ID=34916085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001796 WO2005082561A1 (ja) | 2004-02-27 | 2005-02-08 | コロイダル金属 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005082561A1 (ja) |
WO (1) | WO2005082561A1 (ja) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006193491A (ja) * | 2005-01-17 | 2006-07-27 | Kose Corp | 美白剤、色素沈着抑制剤、α−MSH阻害剤及び皮膚外用剤 |
JP2007326796A (ja) * | 2006-06-06 | 2007-12-20 | Geol Kagaku Kk | 金コロイドを含有する美白剤およびチロシナーゼ阻害剤 |
JP2008125577A (ja) * | 2006-11-17 | 2008-06-05 | Eisuke Imanaga | 薬効成分送達システム、施術用カップ及び薬効成分含有組成物 |
JP2008534675A (ja) * | 2005-04-09 | 2008-08-28 | パイオンテック カンパニー リミテッド | 天然抽出物、ナノシルバー、および天然エッセンシャルオイルを含有する抗菌剤組成物 |
JP2009531547A (ja) * | 2006-03-23 | 2009-09-03 | ザ ユニバーシティー オブ リンカーン | 安定な銀コロイドの調製 |
JP2009242874A (ja) * | 2008-03-31 | 2009-10-22 | Mitsubishi Paper Mills Ltd | 銀超微粒子の製造方法 |
JP2009263719A (ja) * | 2008-04-24 | 2009-11-12 | Toyota Motor Corp | 合金微粒子の製造方法、合金微粒子、該合金微粒子を含む固体高分子型燃料電池用触媒、及び該合金微粒子を含む金属コロイド溶液 |
CN102430761A (zh) * | 2011-12-12 | 2012-05-02 | 池州学院 | 一种可用于灭钉螺的水溶性纳米银的制备方法 |
JPWO2012111834A1 (ja) * | 2011-02-17 | 2014-07-07 | バイオコーク技研株式会社 | 水素を発生する組成物 |
KR101469797B1 (ko) * | 2014-07-22 | 2014-12-12 | 엔프라니 주식회사 | 콜로이달 골드 제비집 추출물을 유효성분으로 함유하는 항노화 화장료 조성물 |
JP2016528164A (ja) * | 2013-04-10 | 2016-09-15 | ユーエックスエヌ シーオー.,エルティーディー. | ゴールドビーズを含有した石鹸組成物または化粧品組成物、およびこれを用いた石鹸の製造方法または化粧品の製造方法 |
CN106442999A (zh) * | 2016-08-31 | 2017-02-22 | 杨世东 | 一种多抗体检测类风湿关节炎的试剂盒及其制备方法 |
JP2018111885A (ja) * | 2005-08-03 | 2018-07-19 | ユニバシダデ デ サンチャゴ デ コンポステラ | 原子量子クラスター、その製造方法およびその使用方法 |
JP2019090111A (ja) * | 2017-11-13 | 2019-06-13 | 国立大学法人北海道大学 | 修飾金属ナノ粒子及び医薬組成物 |
CN111451522A (zh) * | 2020-05-12 | 2020-07-28 | 南通欣颐家纺有限公司 | 一种粒径高度均匀的防蚊、抗菌纳米银溶液制备方法 |
JP2020121927A (ja) * | 2019-01-29 | 2020-08-13 | ロイヤル化粧品株式会社 | 美白用皮膚外用剤 |
JP2022060611A (ja) * | 2020-10-05 | 2022-04-15 | 日本セルフメディカル株式会社 | 美容健康用組成物、及び当該美容健康用組成物を含む医薬品又は飲食品 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59145037A (ja) * | 1983-02-09 | 1984-08-20 | Hidefumi Hirai | 貴金属コロイドを製造する方法 |
JPH03293027A (ja) * | 1990-04-09 | 1991-12-24 | Kao Corp | 金属コロイドの製造法 |
JP2001089140A (ja) * | 1999-09-14 | 2001-04-03 | Japan Science & Technology Corp | 金コロイド粒子とその調製方法並びに金イオンの選択的捕捉方法 |
JP2003213311A (ja) * | 2002-01-22 | 2003-07-30 | Sumitomo Osaka Cement Co Ltd | 金属ナノ粒子の製造方法 |
JP2004008150A (ja) * | 2002-06-10 | 2004-01-15 | Tosoh Corp | 微生物による基質の酸化方法 |
-
2005
- 2005-02-08 WO PCT/JP2005/001796 patent/WO2005082561A1/ja active Application Filing
- 2005-02-08 JP JP2006510385A patent/JPWO2005082561A1/ja not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59145037A (ja) * | 1983-02-09 | 1984-08-20 | Hidefumi Hirai | 貴金属コロイドを製造する方法 |
JPH03293027A (ja) * | 1990-04-09 | 1991-12-24 | Kao Corp | 金属コロイドの製造法 |
JP2001089140A (ja) * | 1999-09-14 | 2001-04-03 | Japan Science & Technology Corp | 金コロイド粒子とその調製方法並びに金イオンの選択的捕捉方法 |
JP2003213311A (ja) * | 2002-01-22 | 2003-07-30 | Sumitomo Osaka Cement Co Ltd | 金属ナノ粒子の製造方法 |
JP2004008150A (ja) * | 2002-06-10 | 2004-01-15 | Tosoh Corp | 微生物による基質の酸化方法 |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006193491A (ja) * | 2005-01-17 | 2006-07-27 | Kose Corp | 美白剤、色素沈着抑制剤、α−MSH阻害剤及び皮膚外用剤 |
JP2008534675A (ja) * | 2005-04-09 | 2008-08-28 | パイオンテック カンパニー リミテッド | 天然抽出物、ナノシルバー、および天然エッセンシャルオイルを含有する抗菌剤組成物 |
JP2018111885A (ja) * | 2005-08-03 | 2018-07-19 | ユニバシダデ デ サンチャゴ デ コンポステラ | 原子量子クラスター、その製造方法およびその使用方法 |
JP7190818B2 (ja) | 2005-08-03 | 2022-12-16 | ユニバシダデ デ サンチャゴ デ コンポステラ | 原子量子クラスター、その製造方法およびその使用方法 |
JP2009531547A (ja) * | 2006-03-23 | 2009-09-03 | ザ ユニバーシティー オブ リンカーン | 安定な銀コロイドの調製 |
JP2007326796A (ja) * | 2006-06-06 | 2007-12-20 | Geol Kagaku Kk | 金コロイドを含有する美白剤およびチロシナーゼ阻害剤 |
JP2008125577A (ja) * | 2006-11-17 | 2008-06-05 | Eisuke Imanaga | 薬効成分送達システム、施術用カップ及び薬効成分含有組成物 |
JP2009242874A (ja) * | 2008-03-31 | 2009-10-22 | Mitsubishi Paper Mills Ltd | 銀超微粒子の製造方法 |
JP2009263719A (ja) * | 2008-04-24 | 2009-11-12 | Toyota Motor Corp | 合金微粒子の製造方法、合金微粒子、該合金微粒子を含む固体高分子型燃料電池用触媒、及び該合金微粒子を含む金属コロイド溶液 |
JPWO2012111834A1 (ja) * | 2011-02-17 | 2014-07-07 | バイオコーク技研株式会社 | 水素を発生する組成物 |
JP6076092B2 (ja) * | 2011-02-17 | 2017-02-08 | バイオコーク技研株式会社 | 皮膚外用組成物 |
CN102430761A (zh) * | 2011-12-12 | 2012-05-02 | 池州学院 | 一种可用于灭钉螺的水溶性纳米银的制备方法 |
JP2016528164A (ja) * | 2013-04-10 | 2016-09-15 | ユーエックスエヌ シーオー.,エルティーディー. | ゴールドビーズを含有した石鹸組成物または化粧品組成物、およびこれを用いた石鹸の製造方法または化粧品の製造方法 |
KR101469797B1 (ko) * | 2014-07-22 | 2014-12-12 | 엔프라니 주식회사 | 콜로이달 골드 제비집 추출물을 유효성분으로 함유하는 항노화 화장료 조성물 |
CN106442999A (zh) * | 2016-08-31 | 2017-02-22 | 杨世东 | 一种多抗体检测类风湿关节炎的试剂盒及其制备方法 |
JP2019090111A (ja) * | 2017-11-13 | 2019-06-13 | 国立大学法人北海道大学 | 修飾金属ナノ粒子及び医薬組成物 |
JP7376901B2 (ja) | 2017-11-13 | 2023-11-09 | 国立大学法人北海道大学 | 修飾金属ナノ粒子及び医薬組成物 |
JP2020121927A (ja) * | 2019-01-29 | 2020-08-13 | ロイヤル化粧品株式会社 | 美白用皮膚外用剤 |
CN111451522A (zh) * | 2020-05-12 | 2020-07-28 | 南通欣颐家纺有限公司 | 一种粒径高度均匀的防蚊、抗菌纳米银溶液制备方法 |
CN111451522B (zh) * | 2020-05-12 | 2021-12-07 | 南通欣颐家纺有限公司 | 一种粒径高度均匀的防蚊、抗菌纳米银溶液制备方法 |
JP2022060611A (ja) * | 2020-10-05 | 2022-04-15 | 日本セルフメディカル株式会社 | 美容健康用組成物、及び当該美容健康用組成物を含む医薬品又は飲食品 |
JP7265271B2 (ja) | 2020-10-05 | 2023-04-26 | 日本セルフメディカル株式会社 | 美容健康用組成物、及び当該美容健康用組成物を含む医薬品又は飲食品 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005082561A1 (ja) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005082561A1 (ja) | コロイダル金属 | |
Abendrot et al. | Zinc‐containing compounds for personal care applications | |
Silva et al. | Trace minerals in human health: Iron, zinc, copper, manganese and fluorine | |
US11931321B2 (en) | Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same | |
EP2452559B1 (en) | Use of a composition having anti-microbial properties | |
Mascarenhas-Melo et al. | Inorganic nanoparticles in dermopharmaceutical and cosmetic products: Properties, formulation development, toxicity, and regulatory issues | |
Fricker | The therapeutic application of lanthanides | |
US20060134226A1 (en) | Compositions useful to treat ocular neovascular diseases and macular degeneration | |
Rahdar et al. | Behavioral effects of zinc oxide nanoparticles on the brain of rats | |
EP1909745A1 (en) | Cosmetic pigment composition containing gold or silver nano-particles | |
EP3801058B1 (fr) | Molecule mimant une activite antioxydante | |
Fu et al. | Transition-Metal-Based Nanozymes: Synthesis, Mechanisms of Therapeutic Action, and Applications in Cancer Treatment | |
Abuid et al. | Biomedical applications of cerium oxide nanoparticles: a potent redox modulator and drug delivery agent | |
Zhou et al. | Biodegradable copper telluride nanosheets for redox-homeostasis breaking-assisted chemodynamic cancer therapy boosted by mild-photothermal effect | |
Sengani et al. | Anti-diabetic efficacy and selective inhibition of methyl glyoxal, intervention with biogenic Zinc oxide nanoparticle | |
Wang et al. | Photothermal therapy of copper incorporated nanomaterials for biomedicine | |
KR100998354B1 (ko) | 불포화 지방산 및 층상형 금속 수산화물의 혼성체, 그 제조방법, 및 그 혼성체를 포함하는 기능성 식품 및 피부외용제 | |
KR20160021734A (ko) | 홍차줄기 추출물을 함유하는 항산화성 조성물 | |
US6376498B1 (en) | Pharmaceutical, cosmetic and/or food composition with antioxidant properties | |
e Silva et al. | Artemia salina Leach in photoprotection: A new model to evaluate the potential of nanoparticles for topical application | |
JP2001322990A (ja) | 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物 | |
Li et al. | Flexible regulation of reactive oxygen species by sustainable cluster drugs | |
Zhao et al. | Cuproptosis: an emerging domain for copper-based nanomaterials mediated cancer therapy | |
KR101758661B1 (ko) | 층상 나노 무기물 및 이의 제조 방법, 및 상기 층상 나노 무기물을 포함하는 식품 보조제 | |
JP2020517726A (ja) | 細胞の解糖系を阻害する方法及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510385 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |